JAMA Oncol 7 (7): 978-984, 2021.[PUBMED Abstract] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med 353 (16): 1659-72, 2005.[PUBMED Abstract] Cameron D, Piccart-Gebhart MJ, Gelber RD, et al.: 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet 389 (10075): 1195-1205, 2017.[PUBMED Abstract] Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.